Cholangiocarcinoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | FGFR2::v | Cholangiocarcinoma | Infigratinib | |
| Sensitivity (+) | IDH1 p.R132C | Cholangiocarcinoma | Ivosidenib | |
| Sensitivity (+) | IDH1 p.R132G | Cholangiocarcinoma | Ivosidenib | |
| Sensitivity (+) | IDH1 p.R132H | Cholangiocarcinoma | Ivosidenib | |
| Sensitivity (+) | IDH1 p.R132L | Cholangiocarcinoma | Ivosidenib | |
| Sensitivity (+) | IDH1 p.R132S | Cholangiocarcinoma | Ivosidenib | |
| Sensitivity (+) | FGFR2::v | Cholangiocarcinoma | Pemigatinib | |
| Sensitivity (+) | FGFR2 rearrangements | Cholangiocarcinoma | Pemigatinib | |
| Sensitivity (+) | HER2-positive | Cholangiocarcinoma | Zanidatamab | |
| Sensitivity (+) | FGFR2::v | Cholangiocarcinoma | Pemigatinib | |
| Sensitivity (+) | FGFR2 rearrangements | Cholangiocarcinoma | Pemigatinib | |
| Sensitivity (+) | IDH1 p.R132S | Cholangiocarcinoma | Ivosidenib | |
| Sensitivity (+) | IDH1 p.R132C | Cholangiocarcinoma | Ivosidenib | |
| Sensitivity (+) | IDH1 p.R132G | Cholangiocarcinoma | Ivosidenib | |
| Sensitivity (+) | IDH1 p.R132H | Cholangiocarcinoma | Ivosidenib | |
| Sensitivity (+) | IDH1 p.R132L | Cholangiocarcinoma | Ivosidenib |